Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $52.25 million for the quarter.
Vanda Pharmaceuticals Stock Performance
Shares of VNDA opened at $4.69 on Friday. The stock has a 50 day simple moving average of $4.66 and a 200 day simple moving average of $4.92. Vanda Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $6.75. The firm has a market capitalization of $273.47 million, a PE ratio of -16.75 and a beta of 0.74.
Insider Activity at Vanda Pharmaceuticals
In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now directly owns 44,857 shares of the company's stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.90% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday. StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Wednesday. They set a "hold" rating for the company.
Get Our Latest Stock Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Company Profile
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
